Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Bristol Myers gets $6.4B Celgene CVR case dismissed: report
A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug
Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...
bovnews6h
BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Zacks.com on MSN8h
Company News for Sep 30, 2024
Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...